溃疡性结肠炎患者启动生物制剂治疗时停用5-氨基水杨酸不增加不良临床结局风险:两项全国性人群队列分析
该研究基于美国Truven MarketScan和丹麦健康登记两个全国性数据库,纳入已口服5-氨基水杨酸(5-ASA)至少90天后启动抗TNF生物制剂的溃疡性结肠炎(UC)患者,比较启动抗TNF后90天内停用与继续使用5-ASA的临床结局。主要复合结局为新用糖皮质激素、UC相关住院或手术。停用5-ASA在美國队列(aHR 1.04;95%CI 0.90-1.21,p=0.57)和丹麦队列(aHR 1.09;95%CI 0.80-1.49,p=0.60)均未增加不良临床事件风险。作者认为结果需在前瞻性临床试验中验证。
要点
- UC患者启动抗TNF时停用5-ASA,美国队列aHR 1.04(95%CI 0.90-1.21),丹麦队列aHR 1.09(95%CI 0.80-1.49),均未增加不良临床事件风险。
- 主要复合结局为新用糖皮质激素、UC相关住院或手术。
- 作者结论认为停用5-ASA不增加不良临床事件风险,但结果需在前瞻性临床试验中验证。
核心结论
- 在两个全国性数据库中,UC患者启动抗TNF治疗时停用5-ASA未增加不良临床事件风险。
- 作者认为这些结果应在前瞻性临床试验中验证。
研究设计与样本
- 研究使用美国Truven MarketScan健康索赔数据库和丹麦健康登记两个全国性数据库。
- 纳入已口服5-ASA至少90天后启动抗TNF的UC患者,共3589例(美国2890例,丹麦699例)。
- 启动抗TNF后90天内停用5-ASA者归为停药组,其余归为继续用药组。
- 采用多变量Cox回归模型校正人口学、临床因素和医疗利用情况,报告停用5-ASA对比继续5-ASA的校正HR(aHR)及95%CI。
主要发现
- 主要结局为任何不良临床事件,定义为新用糖皮质激素、UC相关住院或手术的复合终点。
- 美国队列中,停用5-ASA对比继续5-ASA的aHR为1.04(95%CI 0.90-1.21,p=0.57)。
- 丹麦队列中,停用5-ASA对比继续5-ASA的aHR为1.09(95%CI 0.80-1.49,p=0.60)。
- 敏感性分析考察合并使用免疫调节剂及启动抗TNF前5-ASA治疗持续时间,结果相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为这些结果应在前瞻性临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The benefit of continuing 5-aminosalicylate (5-ASA) in patients with ulcerative colitis (UC) who initiate anti-tumour necrosis factor-alpha (anti-TNF) biologics is unknown. We aimed to compare clinical outcomes in patients with UC already on 5-ASA who started anti-TNF and then either stopped or continued 5-ASA. DESIGN: Our primary outcome was any adverse clinical event defined as a composite of new corticosteroid use, UC-related hospitalisation or surgery. We used two national databases: the United States (US) Truven MarketScan health claims database and the Danish health registers. Patients with UC who started anti-TNF after having been on oral 5-ASA for at least 90 days were included. Patients were classified as stopping 5-ASA if therapy was discontinued within 90 days of starting anti-TNF. We performed multivariable Cox regression models controlling for demographics, clinical factors and healthcare utilisation. Adjusted HRs (aHR) with 95% CI are reported comparing stopping 5-ASA with continuing 5-ASA. RESULTS: A total of 3589 patients with UC were included (2890 US and 699 Denmark). Stopping 5-ASA after initiating anti-TNF was not associated with an increased risk of adverse clinical events in the U.S. cohort (aHR 1.04; 95% CI 0.90 to 1.21, p=0.57) nor in the Danish cohort (aHR 1.09; 95% CI 0.80 to 1.49, p=0.60). Results were similar in sensitivity analyses investigating concomitant immunomodulator use and duration of 5-ASA treatment before initiating anti-TNF. CONCLUSION: In two national databases, stopping 5-ASA in patients with UC starting anti-TNF therapy did not increase the risk of adverse clinical events. These results should be validated in a prospective clinical trial.
引用
- Ungaro RC, Limketkai BN, Jensen CB, et al. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut. 2018. PMID: 30420398. doi:10.1136/gutjnl-2018-317021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。